Navigation Links
Biosensors International to Participate in the 30th Annual J.P. Morgan Healthcare Conference
Date:12/30/2011

SINGAPORE, Dec. 30, 2011 /PRNewswire-Asia/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG:SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices for interventional cardiology and critical care procedures, today announced it will be participating in the 30th Annual J.P. Morgan Healthcare Conference which will be held from 9th to 12th January 2012 in San Francisco, United States.

During this conference, the senior management of Biosensors will present on Thursday, January 12th, 2012 at 11:00am PST within the Asia Healthcare Company Track, and will also meet investors in scheduled one-on-one and small group meetings throughout the conference.

About Biosensors International Group, Ltd.

Listed on the Singapore Stock Exchange (SGX), Biosensors develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation.

With the increasing use of the BioMatrix™ family of drug-eluting stents, we are rapidly emerging as a leader in the global coronary stent market. The recent launch of the Axxess™ self-expanding bifurcation drug-eluting stent and the development of the BioFreedom™ drug-coated stent will further reinforce our market position.

All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with drug-eluting stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water over a six-to-nine-month period as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer‐free stent abluminally coated with BA9, is currently undergoing clinical evaluation.

For more information, please visit www.biosensors.com.

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.

For Biosensors International Group, Ltd.

Mr. Wong Teck Yenn
Director, Investor Relations
Tel: +65-6213-5708
Email: ty.wong@biosensors.com


'/>"/>
SOURCE Biosensors International Group, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Global Biosensors in Medical Diagnostics Industry
2. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
3. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
4. Chindex International, Inc. Announces Management Changes
5. Unprecedented International Effort Seeks to Improve Safety of Orthopedic Devices
6. Chindex International, Inc. Announces Opening of Latest Premium Hospital in Tianjin
7. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
8. Pharmacy Franchise Owners Association: Medicine Shoppe International and Medicap Face Claims Filed by Numerous Franchisees
9. SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases
10. International Isotopes Inc. Announces Conference Call to Give an Update on the Companys General Business Status
11. New MediCare International Excess Options Give up to 50% Premium Discount
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... Canadian Celiac Association (CCA), is pleased to announce the launch of the ... nutritional articles, recipes, and more. The purpose of the GFCP Scoop ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
Breaking Medicine News(10 mins):